Cargando…
PIK3R1(W624R) Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
Identifying cancer drivers and actionable mutations is critical for precision oncology. In epithelial ovarian cancer (EOC) the majority of mutations lack biological or clinical validation. We fully characterized 43 lines of Patient-Derived Xenografts (PDXs) and performed copy number analysis and who...
Autores principales: | D’Ambrosio, Concetta, Erriquez, Jessica, Arigoni, Maddalena, Capellero, Sonia, Mittica, Gloria, Ghisoni, Eleonora, Borella, Fulvio, Katsaros, Dionyssios, Privitera, Silvana, Ribotta, Marisa, Maldi, Elena, Di Nardo, Giovanna, Berrino, Enrico, Venesio, Tiziana, Ponzone, Riccardo, Vaira, Marco, Hall, Douglas, Jimenez-Linan, Mercedes, Paterson, Anna L., Calogero, Raffaele A., Brenton, James D., Valabrega, Giorgio, Di Renzo, Maria Flavia, Olivero, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072782/ https://www.ncbi.nlm.nih.gov/pubmed/32075097 http://dx.doi.org/10.3390/cells9020442 |
Ejemplares similares
-
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer
por: Erriquez, Jessica, et al.
Publicado: (2016) -
A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience
por: Ghisoni, Eleonora, et al.
Publicado: (2018) -
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
por: Ghisoni, Eleonora, et al.
Publicado: (2019) -
Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer
por: Capellero, S., et al.
Publicado: (2020) -
Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives
por: Borella, Fulvio, et al.
Publicado: (2020)